Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy

J. Menczer, M. Modan, J. Brenner, G. Ben-Baruch, H. Brenner

Research output: Contribution to journalArticlepeer-review

Abstract

Abdominopelvic irradiation was given to 18 stage II-IV ovarian carcinoma patients who completed cisplatinum-based combination chemotherapy, were in complete clinical remission, and who underwent second-look laparotomy. The survival as well as the progression-free interval (PFI) was significantly longer in patients with a negative second-look laparotomy than in those with limited residual disease at this operation. Abdominopelvic irradiation was not effective in patients with limited residual disease at second-look laparotomy (3 year survival-34.3% and median PFI from second-look laparotomy-4.8 months). Even in patients with a negative second-look laparotomy the median PFI was only 13 months from this operation and the 3-year survival was 87.5%. The results were similar to other comparable series in which no treatment was administered to patients with a negative second-look laparotomy.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalGynecologic Oncology
Volume24
Issue number2
DOIs
StatePublished - Jun 1986

Fingerprint

Dive into the research topics of 'Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy'. Together they form a unique fingerprint.

Cite this